Viatris’ Mylan Pharmaceuticals and Sun Pharmaceuticals have become the latest targets in lawsuits filed by Novo Nordisk as part of its strategy to fend off the entry of Wegovy (semaglutide) generics into the lucrative US market.
Semaglutide is a GLP-1 agonist, which is marketed under the brand name Wegovy as a weight-loss treatment
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?